Tao Wu

Dr. Tao Wu

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2022 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
HLHeng Liu
Heng Liu
RXRui Xi
Rui Xi
DMDongfeng Mao
Dongfeng Mao
XZXiaochen Zhao
Xiaochen Zhao
TWTao Wu
Tao Wu

3 September 2024 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
YLYang Liu
Yang Liu
WLWenhui Liu
Wenhui Liu
TWTao Wu
Tao Wu

5 January 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
RZRui Zhang
Rui Zhang
WKWei Kou
Wei Kou
TWTao Wu
Tao Wu
RZRui Zhou
Rui Zhou
The myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by cytopenia and a high risk of transformation to acute myeloid leukemia. In recent years, next-generation sequencing (NGS) has revealed common hotspot gene mutations in MDS, which are not only involved in disease progression, but also affect the responsiveness of different therapeutic strategies. Current research has revealed that ASXL1 mutations in MDS predict demethylating agents (HMAs) resistance, the combination of HMAs and Venetoclax (VEN) achieved an ORR of 87%. DNMT 3A R882 mutations induce decitabine sensitivity via hemi-methylated enhancer trapping, and TET2 mutations enhance HMAs efficacy only in ASXL1 wild-type contexts (ORR 62.1% vs. co-mutated 19%). RUNX1 aberrations reduce chemotherapy responses (18.9% ORR in high-risk MDS) through DNA repair impairment, while BCOR/EZH2 loss drives cytarabine resistance. TP53 multi-hit lesions correlate with poor survival (OS <12 months) but respond to eprenetapopt-azacitidine (ORR 73%), and IDH1/2 inhibitors achieve durable remissions (ivosidenib ORR 83.3%, mOS 35.7 months). In this paper, we systematically illustrate the correlation between key gene mutations and the response to HMAs, chemotherapy and targeted therapies in MDS patients. This article summarizes the current evidence on gene mutations as predictive biomarkers and discusses the direction of individualized therapy.

10 August 2024
Verified
Journal Article
Closed access
JZJiawei Zhou
Jiawei Zhou
TWTao Wu
Tao Wu
WLWenhui Liu
Wenhui Liu

1 April 2018
Verified
Journal Article
Closed access
WFWen-Jing Fan
Wen-Jing Fan
ZFZhi-Qiao Fan
Zhi-Qiao Fan
TWTao Wu
Tao Wu
HBHai Bai
Hai Bai

1 August 2016
Verified
Journal Article
Closed access
HZHai-Ying Zhang
Hai-Ying Zhang
QZQiang Zhao
Qiang Zhao
TWTao Wu
Tao Wu